Madopar (Parkinson's Disease) - Forecast and Market Analysis to 2022
|出版日期||內容資訊||英文 62 Pages
|Madopar(帕金森氏症)- 預測與市場分析 Madopar (Parkinson's Disease) - Forecast and Market Analysis to 2022|
|出版日期: 2014年03月31日||內容資訊: 英文 62 Pages||
Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.
Madopar is a combination therapy of levodopa with benserazide hydrochloride, a dopamine decarboxylase inhibitor, developed and marketed by Roche. It is used to treat the signs and symptoms of Parkinson's disease, but does not treat the underlying condition. Similar to other levodopa therapies, over time, patients may show reduced responsiveness to Madopar.